Literature DB >> 3124975

Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.

P Golino1, J H Ashton, P Glas-Greenwalt, J McNatt, L M Buja, J T Willerson.   

Abstract

Human recombinant tissue-type plasminogen activator (rt-PA) has been shown to be an effective and safe agent for coronary thrombolysis in patients with acute myocardial infarction. However, thrombolysis is associated with a high rate of acute reocclusion after discontinuation of rt-PA. The goals of the present study were to assess whether reocclusion after thrombolysis is caused by intracoronary platelet aggregation and to determine the role of thromboxane A2 (TxA2) and serotonin (5HT) in mediating this phenomenon. Accordingly, coronary thrombosis was induced in anesthetized, open-chest dogs by insertion of a copper coil into the left anterior descending coronary artery (LAD). LAD blood flow was monitored throughout the experiment by means of a Doppler flow probe placed proximally to the coil. Thrombolysis was achieved with rt-PA (0.05 mg/kg bolus + micrograms/kg/min infusion) in 23 +/- 3 min. rt-PA was then discontinued and each animal received a bolus of heparin (150 U/kg) every hour. Reperfusion was followed by repeated cycles of gradual occlusions followed by spontaneous restorations of blood flow (cyclic flow variations, CFVs) before a persistent occlusion recurred. In control dogs (n = 6), heparin alone did not prevent CFVs and reocclusion time was 25 +/- 4 min. Administration of an intravenous bolus of 0.2 +/- 0.06 mg/kg SQ29548, a TxA2/prostaglandin H2-receptor antagonist, and an intravenous bolus of 0.2 +/- 0.04 mg/kg ketanserin, a 5HT2-receptor antagonist, completely abolished CFVs in six of six dogs and reocclusion time was greater than 158 +/- 14 min (p less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124975     DOI: 10.1161/01.cir.77.3.678

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Guidelines for the Management of Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

2.  Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction.

Authors:  V L Serebruany; D R Lowry; S Y Fuzailov; D J Levine; C M O'Connor; P A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

3.  Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.

Authors:  D M Vanags; S E Rodgers; E M Duncan; J V Lloyd; F Bochner
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

4.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

Review 5.  Thromboxane synthase inhibitors and receptor antagonists.

Authors:  J Vermylen; H Deckmyn
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

6.  Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 7.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

8.  Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.

Authors:  M J van den Brand; A van Miltenburg; M J de Boer; L R van der Wieken; P J de Feyter; M L Simoons
Journal:  Int J Card Imaging       Date:  1994-09

9.  Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.

Authors:  S J McAuliffe; J A Moors; H B Jones
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 10.  Pharmacologic reperfusion therapy for acute myocardial infarction.

Authors:  Harry C Lowe; Briain D Mac Neill; Frans Van de Werf; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.